JP2011184466A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011184466A5 JP2011184466A5 JP2011143593A JP2011143593A JP2011184466A5 JP 2011184466 A5 JP2011184466 A5 JP 2011184466A5 JP 2011143593 A JP2011143593 A JP 2011143593A JP 2011143593 A JP2011143593 A JP 2011143593A JP 2011184466 A5 JP2011184466 A5 JP 2011184466A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antagonist
- monoclonal antibody
- antibody
- inhibits
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000005557 antagonist Substances 0.000 claims 9
- 102000013264 Interleukin-23 Human genes 0.000 claims 8
- 108010065637 Interleukin-23 Proteins 0.000 claims 8
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 6
- 102000013691 Interleukin-17 Human genes 0.000 claims 6
- 108050003558 Interleukin-17 Proteins 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 6
- 229940126060 IL-17A antagonist Drugs 0.000 claims 5
- 108010076561 Interleukin-23 Subunit p19 Proteins 0.000 claims 5
- 102100036705 Interleukin-23 subunit alpha Human genes 0.000 claims 5
- 206010046851 Uveitis Diseases 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 102100036672 Interleukin-23 receptor Human genes 0.000 claims 1
- 208000018359 Systemic autoimmune disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 108040001844 interleukin-23 receptor activity proteins Proteins 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71379205P | 2005-09-01 | 2005-09-01 | |
| US60/713,792 | 2005-09-01 | ||
| US83731206P | 2006-08-11 | 2006-08-11 | |
| US60/837,312 | 2006-08-11 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008529228A Division JP2009507023A (ja) | 2005-09-01 | 2006-08-30 | 自己免疫性眼炎症性疾患を処置するためのｉｌ−２３およびｉｌ−１７のアンタゴニストの使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013168006A Division JP2014005285A (ja) | 2005-09-01 | 2013-08-13 | 自己免疫性眼炎症性疾患を処置するためのｉｌ−２３およびｉｌ−１７のアンタゴニストの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011184466A JP2011184466A (ja) | 2011-09-22 |
| JP2011184466A5 true JP2011184466A5 (enExample) | 2012-10-04 |
| JP5462838B2 JP5462838B2 (ja) | 2014-04-02 |
Family
ID=37686002
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008529228A Withdrawn JP2009507023A (ja) | 2005-09-01 | 2006-08-30 | 自己免疫性眼炎症性疾患を処置するためのｉｌ−２３およびｉｌ−１７のアンタゴニストの使用 |
| JP2011143593A Expired - Fee Related JP5462838B2 (ja) | 2005-09-01 | 2011-06-28 | 自己免疫性眼炎症性疾患を処置するためのｉｌ−２３およびｉｌ−１７のアンタゴニストの使用 |
| JP2013168006A Pending JP2014005285A (ja) | 2005-09-01 | 2013-08-13 | 自己免疫性眼炎症性疾患を処置するためのｉｌ−２３およびｉｌ−１７のアンタゴニストの使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008529228A Withdrawn JP2009507023A (ja) | 2005-09-01 | 2006-08-30 | 自己免疫性眼炎症性疾患を処置するためのｉｌ−２３およびｉｌ−１７のアンタゴニストの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013168006A Pending JP2014005285A (ja) | 2005-09-01 | 2013-08-13 | 自己免疫性眼炎症性疾患を処置するためのｉｌ−２３およびｉｌ−１７のアンタゴニストの使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (6) | US20080199460A1 (enExample) |
| EP (3) | EP2322219A3 (enExample) |
| JP (3) | JP2009507023A (enExample) |
| CN (1) | CN101296706B (enExample) |
| AT (1) | ATE445415T1 (enExample) |
| AU (1) | AU2006284841B2 (enExample) |
| BR (1) | BRPI0615297A2 (enExample) |
| CA (1) | CA2621086A1 (enExample) |
| CY (1) | CY1110606T1 (enExample) |
| DE (1) | DE602006009834D1 (enExample) |
| DK (1) | DK1933869T3 (enExample) |
| ES (1) | ES2333260T3 (enExample) |
| HR (1) | HRP20100014T1 (enExample) |
| NO (1) | NO20081574L (enExample) |
| NZ (2) | NZ595262A (enExample) |
| PL (1) | PL1933869T3 (enExample) |
| PT (1) | PT1933869E (enExample) |
| RS (1) | RS51142B (enExample) |
| SI (1) | SI1933869T1 (enExample) |
| TW (2) | TWI372061B (enExample) |
| WO (1) | WO2007027761A2 (enExample) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0417487D0 (en) * | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| AU2006342792A1 (en) * | 2005-12-02 | 2007-11-08 | Genentech, Inc. | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL-22R |
| US7910703B2 (en) | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
| WO2007147019A2 (en) | 2006-06-13 | 2007-12-21 | Zymogenetics, Inc. | Il-17 and il-23 antagonists and methods of using the same |
| US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
| CA2679400A1 (en) * | 2007-02-28 | 2008-09-04 | Schering Corporation | Combination therapy for treatment of immune disorders |
| ES2465223T3 (es) * | 2007-04-27 | 2014-06-05 | Zymogenetics, Inc. | Antagonistas de IL-17A, IL-17F e IL-23P19 y procedimientos de uso |
| EP3246045B1 (en) * | 2007-07-26 | 2025-09-03 | Osaka University | Therapeutic agents for ocular inflammatory disease comprising interleukin 6 receptor inhibitor as active ingredient |
| WO2009023267A2 (en) * | 2007-08-15 | 2009-02-19 | President And Fellows Of Harvard College | Methods for modulating development and expansion of il-17 expressing cells |
| WO2009068631A1 (en) | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Method for obtaining polypeptide constructs comprising two or more single domain antibodies |
| WO2009082624A2 (en) * | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
| AU2009204441B2 (en) | 2008-01-09 | 2015-03-05 | The Schepens Eye Research Institute, Inc. | Therapeutic compositions for treatment of ocular inflammatory disorders |
| CN104151428B (zh) * | 2008-02-21 | 2017-07-14 | 麒麟-安姆根有限公司 | Il‑17ra‑il‑17rb拮抗物及其用途 |
| CA2721713C (en) | 2008-05-05 | 2019-07-09 | Novimmune Sa | Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof |
| AU2010203425B2 (en) | 2009-01-09 | 2015-04-09 | The Schepens Eye Research Institute, Inc. | Therapeutic compositions for treatment of corneal disorders |
| US20120014970A1 (en) * | 2009-01-09 | 2012-01-19 | Reza Dana | Therapeutic Compositions for Treatment of Corneal Disorders |
| SG174891A1 (en) * | 2009-04-01 | 2011-11-28 | Genentech Inc | Treatment of insulin-resistant disorders |
| EP2427203B1 (en) | 2009-05-05 | 2018-10-17 | Novimmune S.A. | Anti-il-17f antibodies and use thereof |
| US9301997B2 (en) | 2009-09-21 | 2016-04-05 | Peptinov Sas | Method of vaccination for limiting articular inflammation in rheumatoid arthritis and multiple sclerosis by administering IL-23 peptides |
| SI3295957T1 (sl) | 2010-01-15 | 2020-02-28 | Kirin-Amgen, Inc. | Formulacija protitelesa proti IL-17RA in terapevtski režim za zdravljenje luskavice |
| US20110311527A1 (en) | 2010-06-16 | 2011-12-22 | Allergan, Inc. | IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS |
| SG187231A1 (en) | 2010-07-29 | 2013-02-28 | Eleven Biotherapeutics Inc | Chimeric il-1 receptor type i agonists and antagonists |
| RU2665954C1 (ru) * | 2010-10-08 | 2018-09-05 | Новартис Аг | Способы лечения псориаза с использованием антагонистов il-17 |
| SG190006A1 (en) | 2010-11-04 | 2013-06-28 | Boehringer Ingelheim Int | Anti-il-23 antibodies |
| GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| US20140314798A1 (en) * | 2011-10-21 | 2014-10-23 | Baylor College Of Medicine | Method to measure inflammation in the conjunctiva of patients with tear dysfunction |
| WO2013116682A1 (en) | 2012-02-02 | 2013-08-08 | Ensemble Therapeutics Corporation | Macrocyclic compounds for modulating il-17 |
| CA2868404A1 (en) | 2012-04-05 | 2013-10-10 | F. Hoffmann-La Roche Ag | Bispecific antibodies against human tweak and human il17 and uses thereof |
| CN104507497B (zh) | 2012-05-03 | 2018-10-19 | 勃林格殷格翰国际有限公司 | 抗IL-23p19抗体 |
| ES2711554T3 (es) | 2012-05-22 | 2019-05-06 | Bristol Myers Squibb Co | Anticuerpos biespecíficos contra IL-17A/F IL-23 y sus usos |
| EP2931311A4 (en) * | 2012-12-13 | 2016-08-17 | Merck Sharp & Dohme | LYOPHILIZED BALLULAR PELLETS OF ANTI-IL-23 ANTIBODIES |
| WO2014107737A2 (en) * | 2013-01-07 | 2014-07-10 | Eleven Biotherapeutics, Inc. | Local delivery of il-17 inhibitors for treating ocular disease |
| CN107693781B (zh) | 2013-03-13 | 2021-11-09 | 巴扎德制药公司 | 用于眼部递送的嵌合细胞因子制剂 |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| US9603882B2 (en) | 2013-08-13 | 2017-03-28 | Industrial Technology Research Institute | Method for modulating Th17 cells and method for treating a disease related to modulation of Th17 cells |
| WO2016014775A1 (en) | 2014-07-24 | 2016-01-28 | Boehringer Ingelheim International Gmbh | Biomarkers useful in the treatment of il-23a related diseases |
| AR101753A1 (es) | 2014-09-03 | 2017-01-11 | Boehringer Ingelheim Int | COMPUESTO DE OBJETIVO A IL-23A Y TNF-a Y USO DEL MISMO |
| AR102417A1 (es) * | 2014-11-05 | 2017-03-01 | Lilly Co Eli | Anticuerpos biespecíficos anti-tnf- / anti-il-23 |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| PL3065748T3 (pl) | 2014-12-23 | 2018-07-31 | 4D Pharma Research Limited | Szczep Bacteroides thetaiotaomicron i jego zastosowanie w zmniejszaniu zapalenia |
| KR20170091157A (ko) | 2014-12-23 | 2017-08-08 | 4디 파마 리서치 리미티드 | 피린 폴리펩티드 및 면역 조정 |
| EP3242714B1 (en) | 2014-12-31 | 2021-06-02 | Stimwave Technologies Incorporated | Antenna assembly |
| WO2016123329A2 (en) * | 2015-01-28 | 2016-08-04 | Genentech, Inc. | Gene expression markers and treatment of multiple sclerosis |
| SG10202103879YA (en) | 2015-02-04 | 2021-05-28 | Boehringer Ingelheim Int | Methods of treating inflammatory diseases |
| CN104725514A (zh) * | 2015-02-06 | 2015-06-24 | 中国药科大学 | 新型il23拮抗剂 |
| EA201890050A1 (ru) | 2015-06-15 | 2018-06-29 | 4Д Фарма Рисёрч Лимитед | Композиции, содержащие бактериальные штаммы |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| MD3650033T2 (ro) | 2015-06-15 | 2022-08-31 | 4D Pharma Res Ltd | Compoziții conţinând tulpini bacteriene |
| SI3240554T1 (sl) | 2015-06-15 | 2019-12-31 | 4D Pharma Research Limited, | Blautia stercosis in wexlerae za uporabo v zdravljenju vnetnih in avtoimunskih bolezni |
| HK1258292A1 (zh) | 2015-09-17 | 2019-11-08 | Amgen Inc. | 使用il23途径生物标志物预测il23拮抗剂的临床应答 |
| AU2016357554B2 (en) | 2015-11-20 | 2019-04-04 | Cj Bioscience, Inc. | Compositions comprising bacterial strains |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520631D0 (en) * | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| EP3520801A1 (en) | 2016-03-04 | 2019-08-07 | 4D Pharma Plc | Compositions comprising bacterial blautia strains for treating visceral hypersensitivity |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| TW201821093A (zh) | 2016-07-13 | 2018-06-16 | 英商４Ｄ製藥有限公司 | 包含細菌菌株之組合物 |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| JP7212945B2 (ja) | 2017-05-22 | 2023-01-26 | フォーディー ファーマ リサーチ リミテッド | 細菌株を含む組成物 |
| TW201907931A (zh) | 2017-05-24 | 2019-03-01 | 英商4D製藥研究有限公司 | 包含細菌菌株之組合物 |
| WO2018229188A1 (en) | 2017-06-14 | 2018-12-20 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| MD3804737T2 (ro) | 2017-06-14 | 2022-10-31 | 4D Pharma Res Limited | Compoziții care conțin tulpini bacteriene |
| CN115813955A (zh) | 2017-06-14 | 2023-03-21 | 4D制药研究有限公司 | 包含细菌菌株的组合物 |
| TW202123965A (zh) | 2019-09-09 | 2021-07-01 | 德商百靈佳殷格翰國際股份有限公司 | 抗-il-23p19抗體調配物 |
| US12122839B2 (en) | 2020-08-05 | 2024-10-22 | Synthekine, Inc. | IFNGR binding synthetic cytokines and methods of use |
| WO2022031890A1 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Ifngr2 binding molecules and methods of use |
| JP7819178B2 (ja) | 2020-08-05 | 2026-02-24 | シンセカイン インコーポレイテッド | ＩＬ１０Ｒｂ結合分子および使用方法 |
| US12077594B2 (en) | 2020-08-05 | 2024-09-03 | Synthekine, Inc. | IL2RG binding molecules and methods of use |
| WO2022031870A1 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | IL27Rα BINDING MOLECULES AND METHODS OF USE |
| EP4192880A4 (en) | 2020-08-05 | 2025-04-30 | Synthekine, Inc. | IL10 receptor-binding molecules and methods of use |
| US12012457B1 (en) | 2020-08-05 | 2024-06-18 | Synthekine, Inc. | IL23R binding molecules and methods of use |
| US12291572B2 (en) | 2020-08-05 | 2025-05-06 | Synthekine, Inc. | IL12 receptor synthetic cytokines and methods of use |
| CN116323669A (zh) * | 2020-08-05 | 2023-06-23 | 辛德凯因股份有限公司 | 受体配对相关的组合物和方法 |
| US11859001B2 (en) | 2020-08-05 | 2024-01-02 | Synthekine, Inc. | IL12RB1-Binding molecules and methods of use |
| US12540188B2 (en) | 2020-08-05 | 2026-02-03 | Synthekine, Inc. | IL10Rα/IL2Rγ synthetic cytokines |
| BR112023001723A2 (pt) | 2020-08-05 | 2023-05-02 | Synthekine Inc | Moléculas de ligação à gp130 e métodos de uso |
| CN116829585A (zh) | 2020-08-05 | 2023-09-29 | 辛德凯因股份有限公司 | Il27受体结合相关的组合物和方法 |
| US12234291B2 (en) | 2020-08-05 | 2025-02-25 | Synthekine, Inc. | IL2RB binding molecules and methods of use |
| WO2022031885A2 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Il10ra binding molecules and methods of use |
| KR20240082379A (ko) * | 2021-10-03 | 2024-06-10 | 시스트이뮨, 인코포레이티드 | 암 치료 방법 및 이의 약제학적 조성물 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988001649A1 (en) | 1986-09-02 | 1988-03-10 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| PT1621554E (pt) | 1992-08-21 | 2009-07-13 | Univ Bruxelles | Imunoglobtainas desprovidas de cadeias leves |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| US6838254B1 (en) | 1993-04-29 | 2005-01-04 | Conopco, Inc. | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae |
| US6132764A (en) | 1994-08-05 | 2000-10-17 | Targesome, Inc. | Targeted polymerized liposome diagnostic and treatment agents |
| US6680057B1 (en) * | 1995-03-23 | 2004-01-20 | Immunex Corporation | Methods of treating autoimmune disease by administering interleukin-17 receptor |
| MX9707021A (es) | 1995-03-23 | 1997-11-29 | Immunex Corp | Receptor de il-7. |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| US6326482B1 (en) | 1999-04-23 | 2001-12-04 | Genentech, Inc. | SH2 domain-containing peptides |
| EP1135415B1 (en) | 1998-12-01 | 2010-08-11 | Facet Biotech Corporation | Humanized antibodies to gamma-interferon |
| WO2002008285A2 (en) | 2000-06-22 | 2002-01-31 | Amgen, Inc. | Il-17 molecules and uses thereof |
| WO2002097048A2 (en) | 2001-05-30 | 2002-12-05 | Centocor, Inc. | ANTI-p40 IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES |
| WO2005010044A2 (en) | 2003-07-08 | 2005-02-03 | Genentech, Inc. | Il-17 a/f heterologous polypeptides and therapeutic uses thereof |
| US20050154046A1 (en) | 2004-01-12 | 2005-07-14 | Longgui Wang | Methods of treating an inflammatory-related disease |
| US20070134247A9 (en) | 2002-04-12 | 2007-06-14 | Ramot At Tel Aviv University Ltd. | Prevention of brain inflammation as a result of induced autoimmune response |
| EP1576011B1 (en) * | 2002-10-30 | 2009-08-12 | Genentech, Inc. | Inhibition of il-17 production |
| WO2004071517A2 (en) * | 2003-02-06 | 2004-08-26 | Schering Corporation | Uses of il-23 related reagents |
| ATE440864T1 (de) | 2003-03-10 | 2009-09-15 | Schering Corp | Verwendung von il-23-antagonisten; verwandte reagenzien |
| JP2007515939A (ja) * | 2003-05-09 | 2007-06-21 | セントカー・インコーポレーテツド | ＩＬ−２３ｐ４０特異的免疫グロブリン由来タンパク質、組成物、方法および用途 |
| US7410483B2 (en) | 2003-05-23 | 2008-08-12 | Novare Surgical Systems, Inc. | Hand-actuated device for remote manipulation of a grasping tool |
| AU2005241020B2 (en) * | 2004-05-03 | 2008-07-10 | Merck Sharp & Dohme Corp. | Use of IL-17 expression to predict skin inflammation; methods of treatment |
| US20050287593A1 (en) * | 2004-05-03 | 2005-12-29 | Schering Corporation | Use of cytokine expression to predict skin inflammation; methods of treatment |
| EP1766396B1 (en) | 2004-06-07 | 2010-08-11 | Ramot at Tel-Aviv University Ltd. | Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation |
| JP2008505080A (ja) * | 2004-07-01 | 2008-02-21 | ニューヨーク ユニバーシティー | ＲＯＲγｔ機能の調節のための組成物および方法 |
| DE102005032499B4 (de) * | 2004-07-13 | 2009-10-22 | Lg Electronics Inc. | Dämpfer zur Vibrationsdämpfung und damit ausgerüstete Waschmaschine |
| GB0417487D0 (en) * | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| AR051444A1 (es) | 2004-09-24 | 2007-01-17 | Centocor Inc | Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos |
| WO2006060194A1 (en) * | 2004-11-19 | 2006-06-08 | Synta Pharmaceuticals Corp. | Pyrimidine compounds and uses thereof |
| CA2588449A1 (en) | 2004-11-24 | 2006-06-01 | Therakine Corporation | An implant for intraocular drug delivery |
| TWI363091B (en) * | 2004-12-20 | 2012-05-01 | Schering Corp | Uses of mammalian cytokine; related reagents |
| EA016022B1 (ru) | 2004-12-21 | 2012-01-30 | Сентокор, Инк. | Выделенное антитело млекопитающего против il-12 и способ изменения его активности |
| EP2322553A3 (en) * | 2005-02-14 | 2011-11-16 | Wyeth LLC | Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor |
| CN103146708A (zh) | 2005-06-30 | 2013-06-12 | Abbvie公司 | Il-12/p40结合蛋白 |
| EP2452694B1 (en) * | 2005-06-30 | 2018-11-14 | Janssen Biotech, Inc. | Anti-IL-23 antibodies, compositions, methods and uses |
| LT1931710T (lt) | 2005-08-31 | 2017-03-27 | Merck Sharp & Dohme Corp. | Rekombinantiniai anti-il-23 antikūnai |
| RS55963B1 (sr) | 2005-12-29 | 2017-09-29 | Janssen Biotech Inc | Humana anti-il-23 antitela, kompozicije, metode i upotrebe |
| TW200815469A (en) * | 2006-06-23 | 2008-04-01 | Astrazeneca Ab | Compounds |
-
2006
- 2006-08-30 SI SI200630517T patent/SI1933869T1/sl unknown
- 2006-08-30 RS RSP-2009/0529A patent/RS51142B/sr unknown
- 2006-08-30 PT PT06813945T patent/PT1933869E/pt unknown
- 2006-08-30 CN CN2006800403078A patent/CN101296706B/zh not_active Expired - Fee Related
- 2006-08-30 NZ NZ595262A patent/NZ595262A/xx not_active IP Right Cessation
- 2006-08-30 PL PL06813945T patent/PL1933869T3/pl unknown
- 2006-08-30 BR BRPI0615297-0A patent/BRPI0615297A2/pt not_active IP Right Cessation
- 2006-08-30 ES ES06813945T patent/ES2333260T3/es active Active
- 2006-08-30 JP JP2008529228A patent/JP2009507023A/ja not_active Withdrawn
- 2006-08-30 DK DK06813945.0T patent/DK1933869T3/da active
- 2006-08-30 AU AU2006284841A patent/AU2006284841B2/en not_active Ceased
- 2006-08-30 EP EP10180648.7A patent/EP2322219A3/en not_active Withdrawn
- 2006-08-30 EP EP06813945A patent/EP1933869B1/en not_active Revoked
- 2006-08-30 AT AT06813945T patent/ATE445415T1/de active
- 2006-08-30 WO PCT/US2006/033840 patent/WO2007027761A2/en not_active Ceased
- 2006-08-30 HR HR20100014T patent/HRP20100014T1/hr unknown
- 2006-08-30 CA CA002621086A patent/CA2621086A1/en not_active Abandoned
- 2006-08-30 DE DE602006009834T patent/DE602006009834D1/de active Active
- 2006-08-30 NZ NZ566424A patent/NZ566424A/en not_active IP Right Cessation
- 2006-08-30 US US11/512,622 patent/US20080199460A1/en not_active Abandoned
- 2006-08-30 EP EP09164605A patent/EP2116258A1/en not_active Withdrawn
- 2006-08-31 TW TW095132202A patent/TWI372061B/zh not_active IP Right Cessation
- 2006-08-31 TW TW101115664A patent/TWI463993B/zh not_active IP Right Cessation
-
2008
- 2008-03-31 NO NO20081574A patent/NO20081574L/no not_active Application Discontinuation
-
2009
- 2009-12-21 US US12/643,152 patent/US8524230B2/en not_active Expired - Fee Related
- 2009-12-21 US US12/643,166 patent/US20100111954A1/en not_active Abandoned
-
2010
- 2010-01-12 CY CY20101100034T patent/CY1110606T1/el unknown
-
2011
- 2011-01-28 US US13/015,900 patent/US20110142831A1/en not_active Abandoned
- 2011-06-28 JP JP2011143593A patent/JP5462838B2/ja not_active Expired - Fee Related
-
2013
- 2013-08-06 US US13/960,441 patent/US20130323251A1/en not_active Abandoned
- 2013-08-13 JP JP2013168006A patent/JP2014005285A/ja active Pending
-
2014
- 2014-05-12 US US14/274,905 patent/US20140248279A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wakefield et al. | Scleritis: immunopathogenesis and molecular basis for therapy | |
| EA201370105A1 (ru) | Человеческие антитела против человеческого tnf-подобного лиганда-1а (tl1a) | |
| CA2813849C (en) | Secukinumab for use in the treatment of ankylosing spondylitis | |
| JP2007535930A5 (enExample) | ||
| JP2015508063A5 (enExample) | ||
| JP2012021001A5 (enExample) | ||
| JP2009540018A5 (enExample) | ||
| JP2014205674A5 (enExample) | ||
| WO2008134659A3 (en) | Antagonists to il-17a, il-17f, and il-23p19 and methods of use | |
| UA116194C2 (uk) | Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном | |
| NZ602166A (en) | Antibodies to il-6 and use thereof | |
| UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
| TR201903026T4 (en) | S100A4 ANTIBODIES AND THEIR THERAPEUTIC USES. | |
| JP2016507470A5 (enExample) | ||
| EA201890548A1 (ru) | Антитела к il-23 | |
| HRP20100014T1 (hr) | Uporaba il-23 i il-17 antagonista u liječenju autoimune očne upalne bolesti | |
| JP2013539454A5 (enExample) | ||
| JP2017508475A5 (enExample) | ||
| JP2017113019A5 (enExample) | ||
| JP2016509585A5 (enExample) | ||
| CN112041347A (zh) | 结合人il-4r的抗体、其制备方法和用途 | |
| JP2015530399A5 (enExample) | ||
| EA201290977A1 (ru) | Гуманизированные антитела к il-25 | |
| NZ603191A (en) | Methods for the treatment of il-1b related conditions | |
| JP2014507435A5 (enExample) |